SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces results from a Phase 1b clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in […]
Featured Posts
SEOUL, South Korea–(BUSINESS WIRE)–Hanmi Pharmaceutical Co., Ltd.(KSE: 128940) made an oral presentation on the non-clinical results of once weekly insulin and GLP-1 combination drug ‘LAPSInsulin Combo’ at the 75th American […]
On Thursday, June 4, an advisory committee to the U.S. Food and Drug Administration voted 18-6 to recommend that the agency approve flibanserin (fluh-BANCE-uh-rin), a non-hormonal drug acting on brain chemistry […]
The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.
By John Kamp • Executive Director of the Coalition for Healthcare Communication So, you already know that the 300+ page bill which includes a broad array of amendments related to […]
While development of personalized medicines has grown since the human genome was first sequenced in 2001, biopharmaceutical sponsors face a number of hurdles that are impeding more rapid market uptake, […]
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/7dczrs/essential) has announced the addition of the “Essential Thrombocythemia – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive information on the therapeutic […]
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/gr832s/fabry_disease) has announced the addition of the “Fabry Disease – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive information on the therapeutic […]
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/84dsg4/visceral_pain) has announced the addition of the “Visceral Pain – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive information on the therapeutic […]
The genetically altered, cancer-killing T-cells known as CARTs showed dramatic results in non-Hodgkin lymphoma as the two leading players, the Swiss drug giant Novartis and the Seattle upstart Juno Therapeutics, […]